Knockdown XIST alleviates LPS‐induced WI‐38 cell apoptosis and inflammation injury via targeting miR‐370‐3p/TLR4 in acute pneumonia

Pneumonia is an inflammatory disease that occurs in the lungs associated with pathogens or other factors. It has been well established that long noncoding RNA X inactivate‐specific transcript (XIST) is involved in several cancers. The present study focused on the effect and detailed mechanism of XIS...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell biochemistry and function Jg. 37; H. 5; S. 348 - 358
Hauptverfasser:	Zhang, Yena, Zhu, Yuyin, Gao, Guosheng, Zhou, Zhiming
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Wiley Subscription Services, Inc 01.07.2019 John Wiley and Sons Inc
Schlagworte:	Acute Disease Adult Apoptosis Apoptosis - drug effects Cell injury Cell viability Cells, Cultured Cholecystokinin Cytokines Drug development Enzyme-linked immunosorbent assay Female Fibroblasts Flow cytometry Gene expression Humans Inflammation - chemically induced Inflammation - drug therapy Inflammation - metabolism Inflammatory diseases Inflammatory response Injuries JAK/STAT and NF‐κB pathways Lipopolysaccharides Lipopolysaccharides - antagonists & inhibitors Lipopolysaccharides - pharmacology Lungs Male MicroRNAs - analysis MicroRNAs - antagonists & inhibitors MicroRNAs - metabolism miR‐370‐3p NF-kappa B - metabolism Pneumonia Pneumonia - diagnosis Pneumonia - drug therapy Pneumonia - metabolism RNA, Long Noncoding - biosynthesis RNA, Long Noncoding - genetics RNA, Small Interfering - pharmacology Signal Transduction - drug effects siRNA TLR4 protein Toll-Like Receptor 4 - analysis Toll-Like Receptor 4 - antagonists & inhibitors Toll-Like Receptor 4 - metabolism Toll-like receptors Transcription Transfection Western blotting XIST miR-370-3p JAK/STAT and NF-κB pathways XIST pneumonia
ISSN:	0263-6484, 1099-0844, 1099-0844
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!